NVAX
BUYMeanRevComposite
67.90
Technical
98.60
Fundamental
57.60
Rank
—
Price
12.56
Hurst
0.04
As of
Oct 6, 2026
Daily
Novavax, Inc.
HealthcareBiotechnologyNovavax is a biotechnology firm that creates immunizations against serious infectious illnesses for global markets. The company markets Nuvaxovid, a COVID-19 vaccine, and R21, a malaria vaccine using Matrix-M adjuvant technology. Through partnerships with major pharmaceutical firms including Sanofi and Pfizer, Novavax manufactures and distributes its vaccine candidates internationally.
Market cap
$1.7B
P/E (trailing)
—
P/E (forward)
-61.50
PEG ratio
1.32
Dividend yield
0.00%
Beta
2.44
52w range
6.20 – 13.39
Return on equity
—
Profit margin
-59.87%
Revenue growth
-76.30%
Earnings growth
—
Price history
1Y: 10.08 (+20.0%) · range 6.22–12.82
Cycle position
36/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 50 · WEAK SETUP · exit proximity 0
Conviction
27/ 100 · maturity 57%
VScore.284
Buildup.242
EMA entry setup.3050
Fundamentals.1858
Volume profile
POC
9.21
Price vs POC
+9.5%
Overhead supply
42%
Runway
open sky
Value area 8.40–11.27 · 42% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 0.216 | Oct 12, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -14.31% | +13.25% | 13/20d |
| 40d | -14.31% | +13.25% | 13/40d |